Importantly, consistent with previous reports, our findings also confirm that treatment with MI SNDX-50469 induces differentiation, with upregulation of CD11b expression, associated with loss of viability of AML cells harboring MLL1-r and mtNPM1 [17, 26]. This evidence concerns the gene KMT2A and acute myeloid leukemia.